Drug Profile
BMS 986012
Alternative Names: Anti-fucosyl-GM1 - Bristol-Myers Squibb; BMS986012; Fucosyl-GM1 antibody - Bristol-Myers SquibbLatest Information Update: 24 Feb 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Fucosyl GM1 ganglioside inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Small cell lung cancer
Most Recent Events
- 21 Dec 2022 Bristol-Myers Squibb completes a phase I/II trial in Small cell lung cancer (Second-line therapy or greater, Monotherapy) in USA, Australia, Belgium, Canada, Netherlands, Puerto Rico and South Korea (IV) (NCT02247349) (EudraCT2014-002372-89)
- 08 Apr 2022 Pharmacodynamics data from preclinical studies in Small cell lung cancer presented at the 113th annual meeting of the American Association for Cancer Research (AACR-2022)
- 17 Mar 2021 Phase-II clinical trials in Small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Newly diagnosed) in USA (IV) (NCT04702880)